BioLineRX (BLRX)

• Market cap: $23M
• 1 day: 7.12%
• 5 days: 20.09%
• 1 month: -2.39%
• 3 months: -45.78%
• 6 months: -48.33%
• Year to date: 7.12%
• 1 year: -81.62%
• 5 years: -88.50%
• 10 years: -98.97%

About: BioLine Rx Ltd is a commercial-stage biopharmaceutical company focused on oncology. The company's current development and commercialization pipeline consists of two clinical-stage therapeutic candidates motixafortide (BL-8040), a novel peptide for the treatment of stem-cell mobilization and solid tumors, and AGI-134, an immuno-oncology agent in development for solid tumors. In addition, the company has an off-strategy, legacy therapeutic product called BL-5010 for the treatment of skin lesions. The company has generated revenues from milestone payments under previously existing out-licensing agreements.

Employees: 79

Fund manager confidence

Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)

933% more call options, than puts

Call options by funds: $31K | Put options by funds: $3K

67% more first-time investments, than exits

New positions opened: 5 | Existing positions closed: 3

3% more funds holding

Funds holding: 31 [Q2] → 32 (+1) [Q3]

0.15% less ownership

Funds ownership: 0.36% [Q2] → 0.21% (-0.15%) [Q3]

20% less repeat investments, than reductions

Existing positions increased: 8 | Existing positions reduced: 10

46% less capital invested

Capital invested by funds: $2.46M [Q2] → $1.33M (-$1.13M) [Q3]

Research analyst outlook

1 Wall Street Analyst provided 1 year price targets over the past 3 months

• Low target: $9 3,187% upside
• Avg. target: $9 3,187% upside
• High target: $9 3,187% upside

1 analyst rating

• positive: 1 100%
• neutral: 0 0%
• negative: 0 0%

HC Wainwright & Co. Joseph Pantginis 25% 1-year accuracy 96 / 378 met price target

3,187% upside $9

Buy Maintained

25 Nov 2024